Share-based payments (Tables)

12 Months Ended

Jun. 30, 2026

Disclosure of terms and conditions of share-based payment arrangement [abstract]

Reconciliation of Outstanding Share Based Payments

a. Reconciliation of outstanding share based payments


Series	Grant Date(1)	Expiry Date	Exercise Price	Opening Balance	Granted No. (during the year)	Exercised No. (during the year)	Lapsed/Forfeited* No. (during the year)		Closing Balance	Vested and exercisable No (end of year)
43	18-Jul-18	17-Jul-25	A$1.85	1,773,332		—	(1,773,332)		—	—
43b	18-Jul-18	17-Jul-25	A$1.85	350,000		—	(350,000)		—	—
45	30-Nov-18	29-Nov-25	A$1.31	490,000		(340,000)	(150,000)		—	—
46	19-Jan-19	18-Jan-26	A$1.43	3,333		(3,333)	—		—	—
47	19-Jan-19	18-Jan-26	A$1.43	150,000		(150,000)	—		—	—
48	04-Apr-19	03-Apr-26	A$1.46	300,000		(300,000)	—		—	—
49	20-Jul-19	19-Jul-26	A$1.60	2,081,669		(1,883,335)	—		198,334	198,334
49a	20-Jul-19	19-Jul-26	A$1.45	2,366,666		(1,316,666)	—		1,050,000	700,000
49b	20-Jul-19	19-Jul-26	A$1.45	1,346,667		—	—		1,346,667	1,346,667
49c	20-Jul-19	19-Jul-26	A$1.45	538,667		—	—		538,667	538,667
50	20-Jul-19	19-Jul-26	A$1.45	175,000		(175,000)	—		—	—
54	25-Nov-19	24-Nov-26	A$1.96	20,000		(20,000)	—		—	—
55	29-May-19	28-May-26	A$1.46	350,000		(350,000)	—		—	—
56	18-Nov-19	17-Nov-26	A$1.81	200,000		—	—		200,000	200,000
57	25-Nov-19	24-Nov-26	A$1.78	100,000		—	—		100,000	100,000
58	25-Nov-19	24-Nov-26	A$1.96	150,000		—	—		150,000	150,000
59	24-Jan-20	23-Jan-27	A$3.36	10,000		—	—		10,000	10,000
63	18-May-20	17-May-27	A$4.00	1,200,000		—	—		1,200,000	1,200,000
63a	18-May-20	17-May-27	A$3.63	1,200,000		—	—		1,200,000	1,200,000
64	16-Jul-20	15-Jul-27	A$3.73	3,040,000		—	(80,000)		2,960,000	2,960,000
64a	16-Jul-20	15-Jul-27	A$3.39	1,735,000		—	—		1,735,000	1,013,334
64c	16-Jul-20	15-Jul-27	A$3.39	350,000		—	—		350,000	116,666
64d	16-Jul-20	15-Jul-27	A$3.39	300,000		—	—		300,000	200,000
64e	16-Jul-20	15-Jul-27	A$3.39	1,200,000		—	—		1,200,000	1,200,000
66	11-Sep-20	10-Sep-27	A$4.76	200,000		—	—		200,000	100,000
68	20-Nov-20	19-Nov-27	A$3.58	200,000		—	—		200,000	200,000
69	20-Nov-20	19-Nov-27	A$3.58	100,000		—	—		100,000	100,000
71	17-Feb-21	16-Feb-28	A$2.65	250,000		—	—		250,000	250,000
72	15-Apr-21	14-Apr-28	A$2.26	200,000		—	—		200,000	200,000
74	08-Sep-21	07-Sep-28	A$1.93	2,622,231		(109,231)	(10,000)		2,503,000	2,503,000
74a	08-Sep-21	07-Sep-28	A$1.75	3,850,000		(333,000)	(330,000)	*	3,187,000	2,537,000
74b	08-Sep-21	07-Sep-28	A$1.75	1,550,000		—	—		1,550,000	1,550,000
75	23-Dec-21	22-Dec-28	A$1.40	200,000		—	—		200,000	200,000
76	17-Oct-22	16-Oct-29	A$1.01	1,250,000		—	—		1,250,000	1,250,000
77	23-May-22	22-May-29	A$0.99	200,000		—	—		200,000	200,000
78	24-Aug-22	23-Aug-29	A$0.83	200,000		—	—		200,000	200,000
79	17-Oct-22	16-Oct-29	A$1.11	3,936,166		(1,136,666)	(15,000)	*	2,784,500	2,784,500
79a	17-Oct-22	16-Oct-29	A$1.01	4,170,000		—	(825,000)	*	3,345,000	1,995,000
79b	17-Oct-22	16-Oct-29	A$1.11	225,000		—	—		225,000	225,000
79c	17-Oct-22	16-Oct-29	A$1.01	3,225,000		—	—		3,225,000	2,295,000
79d	17-Oct-22	16-Oct-29	A$1.01	1,200,000		(271,000)	—		929,000	459,000
80	08-Aug-22	07-Aug-29	A$0.91	100,000		—	—		100,000	100,000
81	11-Dec-20	10-Dec-27	A$4.58	100,000		—	—		100,000	100,000
82	21-Nov-22	20-Nov-29	A$1.10	33,333		(33,333)	—		—	—
83	30-Mar-23	29-Mar-30	A$1.01	45,000		(15,000)	—		30,000	30,000
84	30-Mar-23	29-Mar-30	A$0.92	600,000		—	—		600,000	500,000
85	12-Oct-23	11-Oct-30	A$0.36	2,493,835		—	—		2,493,835	2,493,835
86	12-Oct-23	11-Oct-30	A$0.36	1,853,889		—	—		1,853,889	1,853,889
87	16-Oct-23	15-Oct-30	A$0.39	4,744,166		(795,001)	(168,333)	*	3,780,832	2,167,667
87a	16-Oct-23	15-Oct-30	A$0.35	1,668,333		(326,667)	—		1,341,666	245,000


Series	Grant Date(1)	Expiry Date	Exercise Price	Opening Balance	Granted No. (during the year)	Exercised No. (during the year)	Lapsed/Forfeited* No. (during the year)		Closing Balance	Vested and exercisable No (end of year)
87b	16-Oct-23	15-Oct-30	A$0.35	3,160,000		—	—		3,160,000	1,983,334
87c	16-Oct-23	15-Oct-30	A$0.35	1,640,000		(303,333)	—		1,336,667	516,668
88	16-Oct-23	15-Oct-30	A$0.35	447,301		—	—		447,301	447,301
89	24-Oct-23	23-Oct-30	A$0.37	985,000		—	—		985,000	656,666

91	11-Mar-24	10-Mar-31	A$0.32	540,000		—	—		540,000	360,000
92	16-Oct-23	15-Oct-30	A$0.35	300,000		—	—		300,000	200,000
93	30-May-24	29-May-31	A$1.23	220,000		(50,000)	—		170,000	170,000
94	30-May-24	29-May-31	A$1.23	200,000		—	—		200,000	—
95	30-May-24	29-May-31	A$1.35	200,000		(20,000)	—		180,000	115,000
96	10-Sep-24	09-Sep-31	A$0.01	3,594,456		(2,013,528)	—		1,580,928	1,580,928
96a	10-Sep-24	13-Mar-26	A$0.01	2,985,020		(2,985,020)	—		—	—
96b	10-Sep-24	09-Sep-31	A$0.01	346,409		(45,000)	—		301,409	301,409
96c	10-Sep-24	09-Sep-31	A$0.01	2,222,000		—	—		2,222,000	2,222,000
96d	10-Sep-24	13-Mar-26	A$0.01	1,280,651		(1,280,651)	—		—	—
97	27-Aug-24	26-Aug-31	A$1.07	5,822,000		(461,667)	(370,000)	*	4,990,333	1,479,001
97a	27-Aug-24	26-Aug-31	A$0.97	6,800,000		(441,668)	(266,666)	*	6,091,666	1,741,669
97b	27-Aug-24	26-Aug-31	A$0.97	4,839,000		—	—		4,839,000	1,613,001
97c	27-Aug-24	26-Aug-31	A$1.07	240,000		(75,000)	(160,000)	*	5,000	5,000
97d	27-Aug-24	26-Aug-31	A$1.07	225,000		—	—		225,000	75,000
98	14-Oct-24	13-Oct-31	A$1.44	274,223		—	—		274,223	274,223
99	27-Aug-24	26-Aug-31	A$0.97	1,395,389		—	—		1,395,389	1,395,389
100	17-Dec-24	16-Dec-31	A$2.01	10,000		—	(6,666)	*	3,334	3,334
101	17-Dec-24	16-Dec-31	A$1.83	305,260		(233,958)	—		71,302	71,302
102	17-Dec-24	16-Dec-31	A$1.83	235,295		—	—		235,295	235,295
103	10-May-25	09-May-32	A$1.89	155,000		—	(15,000)	*	140,000	46,668
104	10-May-25	09-May-32	A$1.72	215,000		—	—		215,000	215,000
105	10-May-25	09-May-32	A$1.72	197,411		—	—		197,411	197,411
106	10-May-25	09-May-32	A$1.72	100,000		—	—		100,000	—
107	10-May-25	09-May-32	A$1.72		200,000	—	—		200,000	66,667
108	10-May-25	09-May-32	A$1.72		200,000	—	—		200,000	66,667
109	26-Aug-25	25-Aug-32	A$2.46		75,600	—	—		75,600	—
110	26-Aug-25	25-Aug-32	A$2.71		6,385,000	—	(826,000)	*	5,559,000	—
110a	26-Aug-25	25-Aug-32	A$2.46		5,042,000	—	—		5,042,000	—
110b	26-Aug-25	25-Aug-32	A$2.46		2,770,000	—	(278,571)	*	2,491,429	—
110c	26-Aug-25	25-Aug-32	A$2.46		875,000	—	—		875,000	—
111	23-Dec-25	22-Dec-32	A$2.90		650,000	—	—		650,000	—
112	26-Aug-25	25-Aug-32	A$2.46		300,000	—	—		300,000	100,000
113	23-Dec-25	22-Dec-32	A$3.19		300,000	—	—		300,000	—
114	22-Jan-26	21-Jan-33	A$2.85		443,600	—	(30,000)	*	413,600	—
115	26-Feb-26	25-Feb-33	A$2.66		35,000	—	—		35,000	—
116	26-Feb-26	25-Feb-33	A$2.42		400,000	—	—		400,000	—
117	18-May-26	17-May-33	A$2.24		600,000	—	—		600,000	—
118	22-Jan-26	21-Jan-33	A$2.85		600,000	—	—		600,000	—
119	23-Jun-26	22-Jun-33	A$2.16		441,000	—	—		441,000	—
June 30, 2026				93,581,702	19,317,200	(15,468,057)	(5,654,568)		91,776,277	51,811,492
Weighted average share purchase price				A$1.20	A$2.56	A$0.73	A$1.74		A$1.53	A$1.40

(1)The dates presented in the grant date column represent the date on which board approval was obtained. For valuation dates per IFRS 2, refer to Note 17(c).


Series	Grant Date(1)	Expiry Date	Exercise Price	Opening Balance	Granted No. (during the year)	Exercised No. (during the year)	Lapsed/Forfeited* No. (during the year)		Closing Balance	Vested and exercisable No (end of year)
38	16-Sep-17	15-Sep-24	A$1.52	50,000		—	(50,000)		—	—
39	13-Oct-17	12-Oct-24	A$1.92	815,000		—	(815,000)		—	—
39a	13-Oct-17	12-Oct-24	A$1.74	902,425		—	(902,425)		—	—
40	24-Nov-17	23-Nov-24	A$1.39	750,000		—	(750,000)		—	—
40a	24-Nov-17	23-Nov-24	A$1.26	750,000		—	(750,000)	*	—	—
41	18-Jun-18	17-Jun-25	A$1.50	200,000		(200,000)	—		—	—
42	11-Jul-18	10-Jul-25	A$1.54	200,000		(200,000)	—		—	—
43	18-Jul-18	17-Jul-25	A$1.85	2,998,332		(1,225,000)	—		1,773,332	1,773,332
43b	18-Jul-18	17-Jul-25	A$1.85	350,000		—	—		350,000	350,000
45	30-Nov-18	29-Nov-25	A$1.31	590,000		(100,000)	—		490,000	490,000
46	19-Jan-19	18-Jan-26	A$1.43	3,333		—	—		3,333	3,333
47	19-Jan-19	18-Jan-26	A$1.43	150,000		—	—		150,000	150,000
48	04-Apr-19	03-Apr-26	A$1.46	300,000		—	—		300,000	300,000
49	20-Jul-19	19-Jul-26	A$1.60	2,708,669		(627,000)	—		2,081,669	2,081,669
49a	20-Jul-19	19-Jul-26	A$1.45	2,833,332		(466,666)	—		2,366,666	2,016,666
49b	20-Jul-19	19-Jul-26	A$1.45	1,346,667		—	—		1,346,667	1,346,667
49c	20-Jul-19	19-Jul-26	A$1.45	538,667		—	—		538,667	538,667
50	20-Jul-19	19-Jul-26	A$1.45	700,000		(525,000)	—		175,000	—
54	25-Nov-19	24-Nov-26	A$1.96	20,000		—	—		20,000	20,000
55	29-May-19	28-May-26	A$1.46	350,000		—	—		350,000	350,000
56	18-Nov-19	17-Nov-26	A$1.81	200,000		—	—		200,000	200,000
57	25-Nov-19	24-Nov-26	A$1.78	100,000		—	—		100,000	100,000
58	25-Nov-19	24-Nov-26	A$1.96	150,000		—	—		150,000	150,000
59	24-Jan-20	23-Jan-27	A$3.36	10,000		—	—		10,000	10,000
63	18-May-20	17-May-27	A$4.00	1,200,000		—	—		1,200,000	1,200,000
63a	18-May-20	17-May-27	A$3.63	1,200,000		—	—		1,200,000	900,000
64	16-Jul-20	15-Jul-27	A$3.73	3,040,000		—	—		3,040,000	3,040,000
64a	16-Jul-20	15-Jul-27	A$3.39	1,735,000		—	—		1,735,000	1,013,334
64c	16-Jul-20	15-Jul-27	A$3.39	350,000		—	—		350,000	116,666
64d	16-Jul-20	15-Jul-27	A$3.39	300,000		—	—		300,000	200,000
64e	16-Jul-20	15-Jul-27	A$3.39	1,200,000		—	—		1,200,000	1,200,000
66	11-Sep-20	10-Sep-27	A$4.76	200,000		—	—		200,000	100,000
68	20-Nov-20	19-Nov-27	A$3.58	200,000		—	—		200,000	200,000
69	20-Nov-20	19-Nov-27	A$3.58	100,000		—	—		100,000	100,000
71	17-Feb-21	16-Feb-28	A$2.65	250,000		—	—		250,000	250,000
72	15-Apr-21	14-Apr-28	A$2.26	200,000		—	—		200,000	200,000
74	08-Sep-21	07-Sep-28	A$1.93	2,929,666		(290,769)	(16,666)		2,622,231	2,622,231
74a	08-Sep-21	07-Sep-28	A$1.75	3,850,000		—	—		3,850,000	2,780,000
74b	08-Sep-21	07-Sep-28	A$1.75	1,550,000		—	—		1,550,000	620,000
75	23-Dec-21	22-Dec-28	A$1.40	200,000		—	—		200,000	200,000
76	17-Oct-22	16-Oct-29	A$1.01	1,250,000		—	—		1,250,000	833,334
77	23-May-22	22-May-29	A$0.99	200,000		—	—		200,000	200,000
78	24-Aug-22	23-Aug-29	A$0.83	200,000		—	—		200,000	133,334
79	17-Oct-22	16-Oct-29	A$1.11	5,054,500		(1,023,334)	(30,000)		3,936,166	2,278,000
79	17-Oct-22	16-Oct-29	A$1.11				(65,000)	*
79a	17-Oct-22	16-Oct-29	A$1.01	4,350,000		(180,000)	—		4,170,000	1,636,250
79b	17-Oct-22	16-Oct-29	A$1.11	225,000		—	—		225,000	150,000
79c	17-Oct-22	16-Oct-29	A$1.01	3,225,000		—	—		3,225,000	600,000
79d	17-Oct-22	16-Oct-29	A$1.01	1,200,000		—	—		1,200,000	550,000
80	08-Aug-22	07-Aug-29	A$0.91	100,000		—	—		100,000	100,000
81	11-Dec-20	10-Dec-27	A$4.58	100,000		—	—		100,000	100,000
82	21-Nov-22	20-Nov-29	A$1.10	100,000		(66,667)	—		33,333	—


Series	Grant Date(1)	Expiry Date	Exercise Price	Opening Balance	Granted No. (during the year)	Exercised No. (during the year)	Lapsed/Forfeited* No. (during the year)		Closing Balance	Vested and exercisable No (end of year)
83	30-Mar-23	29-Mar-30	A$1.01	45,000		—	—		45,000	30,000
84	30-Mar-23	29-Mar-30	A$0.92	600,000		—	—		600,000	300,000
85	12-Oct-23	11-Oct-30	A$0.36	2,493,835		—	—		2,493,835	2,493,835
86	12-Oct-23	11-Oct-30	A$0.36	1,853,889		—	—		1,853,889	1,853,889
87	16-Oct-23	15-Oct-30	A$0.39	5,434,500		(560,334)	(130,000)	*	4,744,166	1,211,168
87a	16-Oct-23	15-Oct-30	A$0.35	1,995,000		(326,667)	—		1,668,333	—
87b	16-Oct-23	15-Oct-30	A$0.35	3,160,000		—	—		3,160,000	954,667
87c	16-Oct-23	15-Oct-30	A$0.35	2,730,000		(820,000)	(270,000)	*	1,640,000	—
88	16-Oct-23	15-Oct-30	A$0.35	873,393		(426,092)	—		447,301	447,301
89	24-Oct-23	23-Oct-30	A$0.37	985,000		—	—		985,000	328,333
90	28-Feb-24	28-May-24	A$0.01	—		—	—		—	—
91	11-Mar-24	10-Mar-31	A$0.32	—	540,000	—	—		540,000	180,000
92	16-Oct-23	15-Oct-30	A$0.35	300,000		—	—		300,000	100,000
93	30-May-24	29-May-31	A$1.23	220000		—	—		220,000	220000
94	30-May-24	29-May-31	A$1.23	200000		—	—		200,000	—
95	30-May-24	29-May-31	A$1.35		210,000	—	(10,000)		200,000	70,000
96	10-Sep-24	09-Sep-31	A$0.01		5,591,540	(1,997,084)	—		3,594,456	3594456
96a	10-Sep-24	14-Mar-25	A$0.01		3,126,752	(3,126,752)	—		—	—
96a	10-Sep-24	13-Mar-26	A$0.01		7,295,759	(4,310,739)	—		2,985,020	2,985,020
96b	10-Sep-24	09-Sep-31	A$0.01		475,968	(129,559)	—		346,409	346,409
96c	10-Sep-24	09-Sep-31	A$0.01		2,222,000	—	—		2,222,000	2,222,000
96d	10-Sep-24	14-Mar-25	A$0.01		548,851	(548,851)	—		—	—
96d	10-Sep-24	13-Mar-26	A$0.01		1,280,651	—	—		1,280,651	1,280,651
97	27-Aug-24	26-Aug-31	A$1.07		5,852,000	—	(30,000)	*	5,822,000	—
97a	27-Aug-24	26-Aug-31	A$0.97		6,800,000	—	—		6,800,000	—
97b	27-Aug-24	26-Aug-31	A$0.97		4,839,000	—	—		4,839,000	—
97c	27-Aug-24	26-Aug-31	A$1.07		240,000	—	—		240,000	—
97d	27-Aug-24	26-Aug-31	A$1.07		225,000	—	—		225,000	—
98	14-Oct-24	13-Oct-31	A$1.44		274,223	—	—		274,223	91,408
99	27-Aug-24	26-Aug-31	A$0.97		1,395,389	—	—		1,395,389	930,261
100	17-Dec-24	16-Dec-31	A$2.01		235,000	—	(225,000)	*	10,000	—
101	17-Dec-24	16-Dec-31	A$1.83		483,514	—	(178,254)	*	305,260	77,986
102	17-Dec-24	16-Dec-31	A$1.83		235,295	—	—		235,295	—
103	10-May-25	09-May-32	A$1.89		180,000	—	(25,000)	*	155,000	—
104	10-May-25	09-May-32	A$1.72		215,000	—	—		215,000	—
105	10-May-25	09-May-32	A$1.72		197,411	—	—		197,411	98,705
106	10-May-25	09-May-32	A$1.72		100,000	—	—		100,000	—
June 30, 2025				72,416,208	42,563,353	(17,150,514)	(4,247,345)		93,581,702	51,019,572
Weighted average share purchase price				A$1.43	A$0.55	A$0.48	A$1.50		A$1.20	A$1.37

(1)The dates presented in the grant date column represent the date on which board approval was obtained. For valuation dates per IFRS 2, refer to Note 17(c).


Series	Grant Date(1)	Expiry Date	Exercise Price	Opening Balance	Granted No. (during the year)	Exercised No. (during the year)	Lapsed/Forfeited* No. (during the year)	Closing Balance	Vested and exercisable No (end of year)
35a	8-Jul-20	8-Jul-23	US$2.86	1,500,000		—	(1,500,000)	—	—
36	6-Dec-16	5-Dec-23	A$1.31	533,000		—	(533,000)	—	—
36a	6-Dec-16	5-Dec-23	A$1.19	1,950,730		—	(1,950,730)	—	—
38	16-Sep-17	15-Sep-24	A$1.52	50,000		—	—	50,000	50,000


Series	Grant Date(1)	Expiry Date	Exercise Price	Opening Balance	Granted No. (during the year)	Exercised No. (during the year)	Lapsed/Forfeited* No. (during the year)		Closing Balance	Vested and exercisable No (end of year)
39	13-Oct-17	12-Oct-24	A$1.92	975,000		—	(160,000)		815,000	815,000
39a	13-Oct-17	12-Oct-24	A$1.74	902,425		—	—		902,425	902,425
40	24-Nov-17	23-Nov-24	A$1.39	750,000		—	—		750,000	750,000
40a	24-Nov-17	23-Nov-24	A$1.26	750,000		—	—		750,000	—
41	18-Jun-18	17-Jun-25	A$1.50	200,000		—	—		200,000	200,000
42	11-Jul-18	10-Jul-25	A$1.54	200,000		—	—		200,000	200,000
43	18-Jul-18	17-Jul-25	A$1.85	3,133,332		—	(135,000)		2,998,332	2,998,332
43b	18-Jul-18	17-Jul-25	A$1.85	350,000		—	—		350,000	350,000
45	30-Nov-18	29-Nov-25	A$1.31	590,000		—	—		590,000	590,000
46	19-Jan-19	18-Jan-26	A$1.43	3,333		—	—		3,333	3,333
47	19-Jan-19	18-Jan-26	A$1.43	150,000		—	—		150,000	150,000
48	4-Apr-19	3-Apr-26	A$1.46	300,000		—	—		300,000	300,000
49	20-Jul-19	19-Jul-26	A$1.60	3,018,669		—	(310,000)		2,708,669	2,708,669
49a	20-Jul-19	19-Jul-26	A$1.45	2,833,332		—	—		2,833,332	1,883,332
49b	20-Jul-19	19-Jul-26	A$1.45	1,346,667		—	—		1,346,667	673,334
49c	20-Jul-19	19-Jul-26	A$1.45	538,667		—	—		538,667	538,667
50	20-Jul-19	19-Jul-26	A$1.45	700,000		—	—		700,000	175,000
54	25-Nov-19	24-Nov-26	A$1.96	20,000		—	—		20,000	20,000
55	29-May-19	28-May-26	A$1.46	350,000		—	—		350,000	300,000
56	18-Nov-19	17-Nov-26	A$1.81	200,000		—	—		200,000	200,000
57	25-Nov-19	24-Nov-26	A$1.78	100,000		—	—		100,000	100,000
58	25-Nov-19	24-Nov-26	A$1.96	150,000		—	—		150,000	150,000
59	24-Jan-20	23-Jan-27	A$3.36	10,000		—	—		10,000	10,000
63	18-May-20	17-May-27	A$4.00	1,200,000		—	—		1,200,000	1,200,000
63a	18-May-20	17-May-27	A$3.63	1,200,000		—	—		1,200,000	500,000
64	16-Jul-20	15-Jul-27	A$3.73	3,253,333		—	(213,333)		3,040,000	3,040,000
64a	16-Jul-20	15-Jul-27	A$3.39	1,735,000		—	—		1,735,000	478,334
64c	16-Jul-20	15-Jul-27	A$3.39	350,000		—	—		350,000	116,666
64d	16-Jul-20	15-Jul-27	A$3.39	300,000		—	—		300,000	200,000
64e	16-Jul-20	15-Jul-27	A$3.39	1,200,000		—	—		1,200,000	720,000
66	11-Sep-20	10-Sep-27	A$4.76	200,000		—	—		200,000	100,000
68	20-Nov-20	19-Nov-27	A$3.58	200,000		—	—		200,000	200,000
69	20-Nov-20	19-Nov-27	A$3.58	100,000		—	—		100,000	100,000
71	17-Feb-21	16-Feb-28	A$2.65	250,000		—	—		250,000	250,000
72	15-Apr-21	14-Apr-28	A$2.26	200,000		—	—		200,000	200,000
74	8-Sep-21	7-Sep-28	A$1.93	3,186,333		—	(143,335)		2,929,666	1,942,003
74	8-Sep-21	7-Sep-28	A$1.93				(113,332)	*
74a	8-Sep-21	7-Sep-28	A$1.75	3,850,000		—	—		3,850,000	1,653,334
74b	8-Sep-21	7-Sep-28	A$1.75	1,550,000		—	—		1,550,000	620,000
75	23-Dec-21	22-Dec-28	A$1.40	200,000		—	—		200,000	200,000
76	17-Oct-22	16-Oct-29	A$1.01	1,250,000		—	—		1,250,000	416,667
77	23-May-22	22-May-29	A$0.99	200,000		—	—		200,000	133,334
78	24-Aug-22	23-Aug-29	A$0.83	200,000		—	—		200,000	66,667
79	17-Oct-22	16-Oct-29	A$1.11	5,754,500		—	(30,000)		5,054,500	1,668,167
79	17-Oct-22	16-Oct-29	A$1.11				(670,000)	*
79a	17-Oct-22	16-Oct-29	A$1.01	4,350,000		—	—		4,350,000	635,000
79b	17-Oct-22	16-Oct-29	A$1.11	225,000		—	—		225,000	75,000
79c	17-Oct-22	16-Oct-29	A$1.01	3,225,000		—	—		3,225,000	—
79d	17-Oct-22	16-Oct-29	A$1.01	1,200,000		—	—		1,200,000	390,000
80	8-Aug-22	7-Aug-29	A$0.91	100,000		—	—		100,000	100,000
81	11-Dec-20	10-Dec-27	A$4.58	100,000		—	—		100,000	100,000
82	21-Nov-22	20-Nov-29	A$1.10	100,000		—	—		100,000	33,334


Series	Grant Date(1)	Expiry Date	Exercise Price	Opening Balance	Granted No. (during the year)	Exercised No. (during the year)	Lapsed/Forfeited* No. (during the year)		Closing Balance	Vested and exercisable No (end of year)
83	30-Mar-23	29-Mar-30	A$1.01	150,000		—	(105,000)	*	45,000	15,000
84	30-Mar-23	29-Mar-30	A$0.92	—	600,000	—	—		600,000	100,000
85	12-Oct-23	11-Oct-30	A$0.36	—	2,493,835	—	—		2,493,835	831,279
86	12-Oct-23	11-Oct-30	A$0.36	—	1,853,889	—	—		1,853,889	617,965
87	16-Oct-23	15-Oct-30	A$0.39	—	5,459,500	—	(25,000)	*	5,434,500	—
87a	16-Oct-23	15-Oct-30	A$0.35	—	1,995,000	—	—		1,995,000	—
87b	16-Oct-23	15-Oct-30	A$0.35	—	3,160,000	—	—		3,160,000	—
87c	16-Oct-23	15-Oct-30	A$0.35	—	2,730,000	—	—		2,730,000	—
88	16-Oct-23	15-Oct-30	A$0.35	—	873,393	—	—		873,393	291131
89	24-Oct-23	23-Oct-30	A$0.37	—	985,000	—	—		985,000	—
90	28-Feb-24	28-May-24	A$0.01	—	1,072,363	(1,072,363)	—		—	—
92	16-Oct-23	15-Oct-30	A$0.35	—	300,000	—	—		300,000	—
93	30-May-24	29-May-31	A$1.23	—	220,000	—	—		220,000	—
94	30-May-24	29-May-31	A$1.23	—	200,000	—	0		200,000	—
June 30, 2024				57,434,321	21,942,980	(1,072,363)	(5,888,730)		72,416,208	31,061,973
Weighted average share purchase price				A$1.85	A$0.38	A$0.01	A$1.79		A$1.43	A$1.98

(1)The dates presented in the grant date column represent the date on which board approval was obtained. For valuation dates per IFRS 2, refer to Note 17(c).

Summary of Policies Related To Valuations of Options Approved and Granted

This policy applies to all series issued during the year ended June 30, 2026 shown in the above table with the exception of the following:


109						Options were granted in one tranche and are required to satisfy time-based vesting condition. Time-based condition restrict vesting at 12 months.

110a						Options were granted in two, three, or four tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company's board of directors) in the Company achieving certain confidential commercial objectives. Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met.

110b						Options were granted in four or seven tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company's board of directors) in the Company achieving certain confidential commercial objectives. Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met.


110c & 111						Options were granted in four tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met.

116						Options were granted in two equal tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives.

119						Options were granted in three tranches and will vest on the date that the option holder has direct involvement (to the reasonable satisfaction of the Company’s board of directors) in the Company achieving certain confidential commercial objectives. Time-based conditions restrict vesting to a maximum of one third at 12 months, two thirds at 24 months and full grant at 36 months, but only if the pre-specified performance conditions have been met.

Summary of Valuations of Options Approved and Granted

The model inputs for the valuations of options approved and granted during the year ended June 30, 2026 are as follows:


Series	Valuation date(1)	Exercise price per share A$	Share price at valuation date A$	Expected share price volatility	Life(2)	Dividend yield	Risk-free interest rate
107	25-Nov-25	1.72	2.38	73.59%	5.4 yrs	0%	3.92%
108	25-Nov-25	1.72	2.38	73.59%	5.4 yrs	0%	3.92%
109	25-Nov-25	2.46	2.38	73.59%	5.6 yrs	0%	3.92%
110	16-Oct-25	2.71	2.80	73.73%	5.7 yrs	0%	3.55%
110a	10-Apr-26	2.46	2.12	73.27%	5.3 yrs	0%	4.69%
110b	25-Nov-25	2.46	2.38	73.59%	5.6 yrs	0%	3.92%
110c(3)	30-Jun-26	2.46	1.96	72.95%	5.1 yrs	0%	4.40%
111	10-Apr-26	2.90	2.12	73.27%	5.6 yrs	0%	4.69%
112	22-Dec-25	2.46	2.90	73.53%	5.6 yrs	0%	4.33%
113	10-Feb-26	3.19	2.50	73.40%	5.7 yrs	0%	4.40%
114	07-Apr-26	2.85	1.99	73.29%	5.7 yrs	0%	4.70%
115	16-Jun-26	2.66	1.95	72.96%	5.6 yrs	0%	4.48%
116	10-Apr-26	2.42	2.12	73.27%	5.7 yrs	0%	4.69%
117	30-Jun-26	2.24	1.96	72.95%	5.7 yrs	0%	4.40%
118	30-Jun-26	2.85	1.96	72.95%	5.5 yrs	0%	4.40%
119	30-Jun-26	2.16	1.96	72.95%	5.8 yrs	0%	4.40%

(1)Valuation date is the date at which the entity and the employee agree to a share-based payment arrangement, being when the entity and the employee have a shared understanding of the terms and conditions of the arrangement.

(2)Expected life after factoring likely early exercise.

(3)Fair value estimated at June 30, 2026 as the valuation date under IFRS2 has not been met as of June 30, 2026.

The model inputs for the valuations of options approved and granted during the year ended June 30, 2025 are as follows:


Series	Valuation date(1)	Exercise price per share A$	Share price at valuation date A$	Expected share price volatility	Life(2)	Dividend yield	Risk-free interest rate
91	15-Nov-24	0.32	1.57	72.64%	5.3 yrs	0%	4.26%
95	18-Jul-24	1.35	1.11	72.68%	5.8 yrs	0%	3.99%
96	24-Sep-24	0.01	1.06	72.55%	2.6 yrs	0%	3.51%
96a	24-Sep-24	0.01	1.06	72.55%	0.9 yrs	0%	3.51%
96b	24-Sep-24	0.01	1.06	72.55%	2.6 yrs	0%	3.51%
96c	15-Nov-24	0.01	1.57	72.64%	2.6 yrs	0%	4.26%
96d	15-Nov-24	0.01	1.57	72.64%	0.8 yrs	0%	4.26%
97	03-Oct-24	1.07	1.35	72.55%	5.8 yrs	0%	3.63%
97a	16-Dec-24	0.97	1.83	72.65%	5.7 yrs	0%	3.95%
97b	17-Dec-24	0.97	1.94	72.65%	5.7 yrs	0%	3.93%
97c	20-Dec-24	1.07	2.42	73.89%	5.6 yrs	0%	4.08%
97d	25-Jun-25	1.07	1.61	73.60%	5.2 yrs	0%	3.43%
98	17-Apr-25	1.44	1.65	73.83%	5.5 yrs	0%	3.58%
99	15-Nov-24	0.97	1.57	72.64%	5.7 yrs	0%	4.26%
100	20-Dec-24	2.01	2.42	73.89%	5.9 yrs	0%	4.08%
101	24-Apr-25	1.83	1.79	73.83%	5.6 yrs	0%	3.56%
102	07-May-25	1.83	1.72	73.77%	5.6 yrs	0%	3.59%
103	25-Jun-25	1.89	1.61	73.60%	5.8 yrs	0%	3.43%
104	15-Jan-26	1.72	2.70	73.47%	5.3 yrs	0%	4.22%
105	06-Jun-25	1.72	1.76	73.64%	5.9 yrs	0%	3.57%
106	05-Jun-25	1.72	1.77	73.65%	5.9 yrs	0%	3.54%

(2)Expected life after factoring likely early exercise.

The model inputs for the valuations of options approved and granted during the year ended June 30, 2024 are as follows:


Series	Valuation date(1)	Exercise price per share A$	Share price at valuation date A$	Expected share price volatility	Life(2)	Dividend yield	Risk-free interest rate
84	31-Jul-23	0.92	1.18	64.95%	6.1 yrs	0%	3.84%
85	28-Nov-23	0.36	0.39	69.82%	6.3 yrs	0%	4.21%
86	28-Nov-23	0.36	0.39	69.82%	6.3 yrs	0%	4.21%
87	09-Jan-24	0.39	0.29	70.10%	6.2 yrs	0%	3.79%
87a	03-Jun-24	0.35	1.17	72.84%	5.8 yrs	0%	4.07%
87b	12-Jan-24	0.35	0.29	70.07%	6.1 yrs	0%	3.74%
87c	29-Jul-24	0.35	1.07	72.76%	5.6 yrs	0%	3.99%
88	15-Nov-23	0.35	0.37	69.82%	6.3 yrs	0%	4.23%
89	28-Nov-23	0.37	0.39	69.82%	6.3 yrs	0%	4.21%
90	28-Feb-24	0.01	0.30	69.97%	0.2 yrs	0%	3.80%
92	11-Apr-24	0.35	0.89	72.66%	5.9 yrs	0%	3.90%
93	03-Jun-24	1.23	1.17	72.84%	6.4 yrs	0%	4.07%
94	14-Oct-24	1.23	1.44	72.56%	5.6 yrs	0%	3.89%

(2)Expected life after factoring likely early exercise.